Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Alzheimer’s Disease is a neurological condition that impacts memory, behavior, and cognition. It is the most prevalent form of dementia and a leading cause of mortality worldwide. In 2023, approximately 32 million people were diagnosed with Alzheimer’s Disease in G7 countries (Canada, France, Germany, Italy, Japan, UK and the US). The life expectancy is typically 7 to 10 years for those diagnosed with Alzheimer’s Disease at 60 to 70 years old.

There are currently over 70 assets in Phase II or later clinical trials for the treatment of Alzheimer’s Disease, in an effort to prevent, manage or delay symptoms.

In the new Therapy Watch Alzheimer’s Disease study, patient record form (PRF) insights are collected through online interviews with a panel of Neurologists, GPs, Geriatricians, and Physiatrists who specialize in early-stage Alzheimer’s Disease patients. By targeting these specialists, we aim to gain a comprehensive understanding of the complete patient journey and the collaborative efforts of the multidisciplinary team in combating this disease.

The patient records are exceptionally thorough, encompassing vital information such as patient demographics, diagnostic tests including innovative imaging and biomarker tests, detailed symptoms and associated conditions of Alzheimer’s Disease, current treatments, and uptake of new treatment launches.

Therapy Watch is a syndicated market tracking tool that provides market researchers and marketing teams and with real-world evidence into prescribing behaviors and market dynamics. Contact us today to learn more about our new Alzheimer’s Disease study and how it could help address your business questions.